Skip to main content
. Author manuscript; available in PMC: 2018 Jan 18.
Published in final edited form as: Int J Cancer. 2016 Jan 21;139(1):85–98. doi: 10.1002/ijc.29911

Figure 2. Study-specific and pooled relative risks (RR) corresponding to the proportion of HPV DNA+ cases that were p16INK4a + relative to the proportion of HPV DNA− cases that were p16INK4a +.

Figure 2